Green and pink spheres with spikes with pink helix design on blue background

This material reflects the GSK research pipeline as of
February 6, 2023

Pipeline

Our unique R&D approach of Science x Technology x Culture is helping to fight cancer on multiple groundbreaking fronts - focusing on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential.

Resources

Pipeline Brochure

Pipeline Wall

DREAMM Trials

CD226 Axis

4 Key Areas of Cancer Research

KEY AREAS OF CANCER RESEARCH

13* Clinical Assets

CLINICAL ASSETS

* Includes an asset and trials in collaboration and license alliance with iTeos Therapeutics and assets and trials in-license or from other partnership with third parties

40* Gsk Oncology Pipeline Clinical Trials Currently Underway

GSK ONCOLOGY PIPELINE CLINICAL TRIALS CURRENTLY UNDERWAY

* Includes an asset and trials in collaboration and license alliance with iTeos Therapeutics and assets and trials in-license or from other partnership with third parties

Immuno-Oncology

Harnessing The Body’s Immune System

The growing understanding of tumor cells' ability to evade immune surveillance has led to advances in the field of immuno-oncology.1

Malignant cells manipulate a variety of physiological mechanisms involved in antigenicity, immune activation, T-cell priming and recruitment, and upregulation of checkpoint molecules.1 Many of these mechanisms may be impacted simultaneously to promote tumor cell survival.1 Immunotherapies harness the body's own immune system to fight cancer by using different immunological pathways to enhance antitumor responses.1,2

GSK is exploring different clinical assets aimed at augmenting the immune response, reducing immune suppression, and modulating the tumor microenvironment.3,4

Tumor Cell Targeting

Targeting Cancer Cell-Specific Alterations

Cancer cells exhibit differences from somatic cells due to alterations that promote growth, proliferation, survival, and metastasis.5 These tumor-specific attributes can be selectively targeted through established modalities such as antibody-drug conjugates (ADCs); small molecules, like Janus kinase (JAK) and bone morphogenetic protein receptor kinase activin A receptor, type I (ACVR1) inhibitors; and other biological therapies, including gene therapy.5-8 GSK is investigating multiple targeted cell therapies in ongoing clinical studies.9

Synthetic Lethality

Inhibiting Pathways That Contribute to Aberrant DNA Repair and Cellular Metabolism

Accumulation of DNA damage, genomic instability, and altered cellular metabolism are pervasive characteristics of human tumors.10-12 Disruption of essential DNA damage repair or cellular metabolism in cancer cells may increase dependency on alternate repair pathways for cell survival or make tumors more susceptible to modulation of metabolic enzymes.11,13 Synthetically lethal therapies aim to combine pharmacologic inhibition of targeted pathways with tumor-inherent defects in key cellular processes that promote aberrant proliferation to selectively kill tumor cells while sparing healthy tissue.11,13-15 GSK is investigating clinical assets that utilize the power of synthetically lethal interactions to fight malignant cells in a variety of cancers94

Footnotes

*In-license or other partnership with third party.

†Collaboration between GSK and Tempus.

‡The trial is no longer enrolling patients with endometrial cancer.

§Collaboration and License Alliance between GSK and iTeos Therapeutics.

ᶳIn collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups.

Sierra Oncology, Inc., a GSK company. 

£Not yet recruiting as of February 10, 2023.

References

  1. Allard B et al. Semin Cancer Biol. 2018;52(pt 2):1-11. doi:10.1016/j.semcancer.2018.02.005
  2. Medicines in development for immuno-oncology 2017 report. PhRMA. June 1, 2017. Accessed January 30, 2019. https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/MID-Reports/MID-Report-Immuno_Oncology-2017.PDF.
  3. Tai YT, Anderson KC. Immunotherapy. 2015;7(11):1187-1199.
  4. Kumar S et al. MAbs. 2021;13(1):1954136. doi:10.1080/19420862.2021.1954136
  5. Lee YT et al. Eur J Pharmacol. 2018;834:188-196
  6. Hafeez U et al. Molecules. 2020;25(20):4764. doi:10.3390/molecules25204764
  7. Levavi H et al. Clin Adv Hematol Oncol. Accessed October 3, 2022. www.clinicaltrials.gov/
  8. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188-196.
  9. Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25(20):4764. doi:10.3390/molecules25204764.
  10. Levavi H et al. Clin Adv Hematol Oncol.2022;20(7):456-467.
  11. Asshoff M et al. Blood. 2017;129(13):1823-1830.
  12. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287-294.
  13. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560.
  14. Coller HA. Is cancer a metabolic disease? Am J Pathol. 2014;184(1):4-17.
  15. Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 2016;15(3):574-587.
  16. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what’s new? Future Oncol. 2014;10(7):1215-1237.
  17. O’Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18(10):613-623.

 

Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

LOCs to insert local adverse events reporting procedure.

© 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.

SE-GBL-ON-WCNT-200001 | April 2023